Institutional Review Board (IRB) Submissions


Research teams should document which members of their team will be responsible for managing U-M Institutional Review Board Medical School (IRBMED) applications in eResearch or other regulatory management systems. Additional documentation should include:

  • Tracking tools for annual renewals and other document due dates

Failure to submit your annual renewal in a timely manner could result in study expiry and halt of research

  • Responsibility for reporting other information to the IRB such as ORIOS, AES, and reports

As stated in the FDA Information Sheets, if a lapse in IRB approval occurs, all research should stop and no new subjects should be enrolled. Please refer to the IRBMED website and then click on the AE/ORIO Guidance for reporting instructions regarding Adverse Events (AEs), Other Reportable Information and Occurrences (ORIOs), and Protocol Deviations.

IRBs are required to function under written procedures; one of these procedural requirements (21 CRF 56.108 a 3) requires ensuring prompt reporting to the IRB of changes in a research activity. For example, the completion of a study is a change in activity and should be reported to the IRB.

Related Resources

Title 21 CFR 56.108 IRB functions and operations

U-M Institutional Review Board Medical School (IRBMED)

HRPP Operations Manual (OM)

Standard Practice Guideline (SPG) Templates for Clinical Trials

Downloadable Templates and Appendices

IRB Submissions.docx


Contact us at

Was this article helpful?

Can’t find what you’re looking for?

Subscribe to Breakthrough, MICHR’s monthly e-newsletter